Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Abroad (travel likely)RecruitingPHASE3

Conditions

Ovarian · Primary Peritoneal · Fallopian Tube Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Affiliated Cancer Hospital of Chongqing University, Chongqing, Chongqing Municipality, China
Contact: Study coordinator (Qi Zhou) · qizhou9128@163.com · 023-65311341
Contact: Principal Investigator (Qi Zhou, PhD)
Contact: Principal Investigator (Tao Zhu, PhD)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · La Jolla, United States

A Beta-only IL-2 ImmunoTherapY Study

Advanced Solid Tumor · Unresectable Solid Tumor · Clear Cell Renal Cell Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

San Diego, United States · San Francisco, United States

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

Ovarian Cancer · Advanced Ovarian Carcinoma · Fallopian Tube Carcinoma

Abroad (travel likely)Recruiting

Aurora, United States · Boulder, United States

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Cancer · Breast Cancer · Non-Small Cell Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China